1887

Abstract

Most retroviruses induce severe immunosuppression during acute infection. We have used the Friend retrovirus mouse model to demonstrate that immunostimulatory B-type CpG oligodeoxynucleotides (ODN) have a protective effect against retrovirus-induced suppression of antibody responses to potent B-cell antigens. CD8 T cells were critical for effective treatment with CpG-ODN, since depletion of these cells from treated mice impaired protection from retrovirus-induced immunosuppression. Protection also required IFN-, as neutralization of this cytokine abolished the therapeutic effect of CpG-ODN. These findings may have implications for the treatment of immunosuppressive virus infections.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.81115-0
2005-12-01
2020-10-30
Loading full text...

Full text loading...

/deliver/fulltext/jgv/86/12/3365.html?itemId=/content/journal/jgv/10.1099/vir.0.81115-0&mimeType=html&fmt=ahah

References

  1. Chesebro B., Miyazawa M., Britt W. J. 1990; Host genetic control of spontaneous and induced immunity to Friend murine retrovirus infection. Annu Rev Immunol 8:477–499 [CrossRef]
    [Google Scholar]
  2. Dittmer U., Race B., Peterson K. E., Stromnes I. M., Messer R. J., Hasenkrug K. J. 2002; Essential roles for CD8+ T cells and gamma interferon in protection of mice against retrovirus-induced immunosuppression. J Virol 76:450–454 [CrossRef]
    [Google Scholar]
  3. Equils O., Schito M. L., Karahashi H., Madak Z., Yarali A., Michelsen K. S., Sher A., Arditi M. 2003; Toll-like receptor 2 (TLR2) and TLR9 signaling results in HIV-long terminal repeat trans -activation and HIV replication in HIV-1 transgenic mouse spleen cells: implications of simultaneous activation of TLRs on HIV replication. J Immunol 170:5159–5164 [CrossRef]
    [Google Scholar]
  4. Faxvaag A., Espevik T., Dalen A. 1995; An immunosuppressive murine leukaemia virus induces a Th1→Th2 switch and abrogates the IgM antibody response to sheep erythrocytes by suppressing the production of IL-2. Clin Exp Immunol 102:487–495
    [Google Scholar]
  5. Hasenkrug K. J., Brooks D. M., Dittmer U. 1998; Critical role for CD4+ T cells in controlling retrovirus replication and spread in persistently infected mice. J Virol 72:6559–6564
    [Google Scholar]
  6. Hornung V., Rothenfusser S., Britsch S., Krug A., Jahrsdorfer B., Giese T., Endres S., Hartmann G. 2002; Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 168:4531–4537 [CrossRef]
    [Google Scholar]
  7. Kabat D. 1989; Molecular biology of Friend viral erythroleukemia. Curr Top Microbiol Immunol 148:1–42
    [Google Scholar]
  8. Krieg A. M. 2001; Now I know my CpGs. Trends Microbiol 9:249–252 [CrossRef]
    [Google Scholar]
  9. Krieg A. M., Yi A. K., Matson S., Waldschmidt T. J., Bishop G. A., Teasdale R., Koretzky G. A., Klinman D. M. 1995; CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546–549 [CrossRef]
    [Google Scholar]
  10. Olbrich A. R. M., Schimmer S., Heeg K., Schepers K., Schumacher T. N., Dittmer U. 2002; Effective postexposure treatment of retrovirus-induced disease with immunostimulatory DNA containing CpG motifs. J Virol 76:11397–11404 [CrossRef]
    [Google Scholar]
  11. Olbrich A. R. M., Schimmer S., Dittmer U. 2003; Preinfection treatment of resistant mice with CpG oligodeoxynucleotides renders them susceptible to Friend retrovirus-induced leukemia. J Virol 77:10658–10662 [CrossRef]
    [Google Scholar]
  12. Scheller C., Ullrich A., McPherson A. 10 other authors 2004; CpG oligodeoxynucleotides activate HIV replication in latently infected human T cells. J Biol Chem 279:21897–21902 [CrossRef]
    [Google Scholar]
  13. Schlaepfer E., Audige A., von Beust B., Manolova V., Weber M., Joller H., Bachmann M. F., Kundig T. M., Speck R. F. 2004; CpG oligodeoxynucleotides block human immunodeficiency virus type 1 replication in human lymphoid tissue infected ex vivo. J Virol 78:12344–12354 [CrossRef]
    [Google Scholar]
  14. Stromnes I. M., Dittmer U., Schumacher T. N., Schepers K., Messer R. J., Evans L. H., Peterson K. E., Race B., Hasenkrug K. J. 2002; Temporal effects of gamma interferon deficiency on the course of Friend retrovirus infection in mice. J Virol 76:2225–2232 [CrossRef]
    [Google Scholar]
  15. Sun S., Kishimoto H., Sprent J. 1998; DNA as an adjuvant: capacity of insect DNA and synthetic oligodeoxynucleotides to augment T cell responses to specific antigen. J Exp Med 187:1145–1150 [CrossRef]
    [Google Scholar]
  16. Teleshova N., Kenney J., Jones J. 7 other authors 2004; CpG-C immunostimulatory oligodeoxyribonucleotide activation of plasmacytoid dendritic cells in rhesus macaques to augment the activation of IFN-gamma-secreting simian immunodeficiency virus-specific T cells. J Immunol 173:1647–1657 [CrossRef]
    [Google Scholar]
  17. Verthelyi D., Gursel M., Kenney R. T., Lifson J. D., Liu S., Mican J., Klinman D. M. 2003; CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection. J Immunol 170:4717–4723 [CrossRef]
    [Google Scholar]
  18. Verthelyi D., Wang V. W., Lifson J. D., Klinman D. M. 2004; CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques. AIDS 18:1003–1008 [CrossRef]
    [Google Scholar]
  19. Walker P. S., Scharton-Kersten T., Krieg A. M., Love-Homan L., Rowton E. D., Udey M. C., Vogel J. C. 1999; Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms. Proc Natl Acad Sci U S A 96:6970–6975 [CrossRef]
    [Google Scholar]
  20. Yamamoto S., Yamamoto T., Shimada S., Kuramoto E., Yano O., Kataoka T., Tokunaga T. 1992; DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol Immunol 36:983–997 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.81115-0
Loading
/content/journal/jgv/10.1099/vir.0.81115-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error